Sarcopenia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global sarcopenia treatment market has witnessed a substantial surge in recent years, thanks to a growing aging population and a heightened interest in preventive healthcare. The market has seen a significant rise in the sale of vitamins, proteins, minerals, and nutritional and herbal supplements for sarcopenia treatment. This trend is expected to continue as consumers in the U.S., Europe, and Japan increasingly turn to supplements to maintain their health and combat malnutrition-related diseases.

Key Findings:

Health-Conscious Consumer Base:

Approximately 30% of vitamin and dietary supplement sales in the U.S. were to consumers aged 65 and above. The increasing adoption of supplements among the aging population, driven by growing health consciousness, is a major factor boosting the demand for sarcopenia treatment and supplements.

Aging Population and Out-of-Pocket Healthcare Expenditure:

With the global population projected to increase, people aged 65 and older constitute a rapidly growing demographic. The prevalence of sarcopenia is high among this age group, contributing to the market's growth. Additionally, increasing out-of-pocket healthcare expenditure has further fueled the demand for sarcopenia treatment supplements.

Reinforcement of Research Activities for Sarcopenia:

Despite being a common condition, sarcopenia lacks proper treatment options. Consequently, many manufacturers are intensifying their research and development efforts to address this issue. Companies and organizations such as Nestle, Novartis, GSK, EWGSOP, and the International Osteoporosis Organization are actively conducting clinical trials and research for age-related muscle mass loss, offering promising developments in drug treatments.

Investments for Drug and Supplement Development:

Major pharmaceutical and food-processing companies are investing in the development of new nutrition supplements aimed at treating sarcopenia. Some are even collaborating with startups to invest in early-stage nutraceutical businesses, illustrating a commitment to tackling this health concern.

Malnutrition and Vitamin Deficiency in Developing Countries:

Malnutrition, especially prevalent in developing and underdeveloped countries, is a leading cause of sarcopenia. Regions such as Latin America, Africa, and Southeast Asia suffer from high malnutrition rates, driving an increased demand for sarcopenia treatment supplements. The rise in vitamin D and vitamin B12 deficiencies among vegetarian and elderly populations further contributes to the demand for these supplements.

Key Market Players:

Abbott Laboratories, Pfizer Inc., GlaxoSmithKline Plc., Nestle S.A., Sanofi S.A., Bayer AG, Amway, Novartis AG, Cadila Healthcare Ltd., Eli Lilly and Company, and others are prominent players in the sarcopenia treatment market. These companies are adopting innovative marketing and sales strategies, including online product offerings and digital marketing, to enhance their market penetration.

The global sarcopenia treatment market encompasses a range of supplements, including protein, amino acids, creatine, omega-3 acids, vitamin D, vitamin B12, and calcium carbonate. These supplements play a crucial role in preventing accelerated muscle loss and maintaining energy during periods of muscle disuse.

Market Segmentation:

The report presents a detailed taxonomy of the sarcopenia treatment market, categorized by treatment type, distribution channel, and region. Treatment types in the global sarcopenia treatment market include protein supplements, vitamin D & calcium supplements, and vitamin B12 supplements. Distribution channels encompass hospital pharmacies, retail pharmacies, online pharmacies, and hypermarkets & supermarkets. The sarcopenia treatment market has been examined across regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa.

1. Executive Summary

1.1. Global Sarcopenia Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Sarcopenia Treatment Market Outlook, 2018 - 2031

3.1. Global Sarcopenia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Protein Supplement
  - 3.1.1.2. Vitamin B12 Supplement
  - 3.1.1.3. Vitamin D & Calcium Supplement
3.2. Global Sarcopenia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Hospital Pharmacies
  - 3.2.1.2. Retail Pharmacies
  - 3.2.1.3. Online Pharmacies
  - 3.2.1.4. Hypermarket & Supermarket
3.3. Global Sarcopenia Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Sarcopenia Treatment Market Outlook, 2018 - 2031

4.1. North America Sarcopenia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Protein Supplement
  - 4.1.1.2. Vitamin B12 Supplement
  - 4.1.1.3. Vitamin D & Calcium Supplement
4.2. North America Sarcopenia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Hospital Pharmacies
  - 4.2.1.2. Retail Pharmacies
  - 4.2.1.3. Online Pharmacies
  - 4.2.1.4. Hypermarket & Supermarket
4.3. North America Sarcopenia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Sarcopenia Treatment Market Outlook, 2018 - 2031

5.1. Europe Sarcopenia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Protein Supplement
  - 5.1.1.2. Vitamin B12 Supplement
  - 5.1.1.3. Vitamin D & Calcium Supplement
5.2. Europe Sarcopenia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Hospital Pharmacies
  - 5.2.1.2. Retail Pharmacies
  - 5.2.1.3. Online Pharmacies
  - 5.2.1.4. Hypermarket & Supermarket
5.3. Europe Sarcopenia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Sarcopenia Treatment Market Outlook, 2018 - 2031

6.1. Asia Pacific Sarcopenia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Protein Supplement
  - 6.1.1.2. Vitamin B12 Supplement
  - 6.1.1.3. Vitamin D & Calcium Supplement
6.2. Asia Pacific Sarcopenia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Hospital Pharmacies
  - 6.2.1.2. Retail Pharmacies
  - 6.2.1.3. Online Pharmacies
  - 6.2.1.4. Hypermarket & Supermarket
6.3. Asia Pacific Sarcopenia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Sarcopenia Treatment Market Outlook, 2018 - 2031

7.1. Latin America Sarcopenia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Protein Supplement
  - 7.1.1.2. Vitamin B12 Supplement
  - 7.1.1.3. Vitamin D & Calcium Supplement
7.2. Latin America Sarcopenia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Hospital Pharmacies
  - 7.2.1.2. Retail Pharmacies
  - 7.2.1.3. Online Pharmacies
  - 7.2.1.4. Hypermarket & Supermarket
7.3. Latin America Sarcopenia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Sarcopenia Treatment Market Outlook, 2018 - 2031

8.1. Middle East & Africa Sarcopenia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Protein Supplement
  - 8.1.1.2. Vitamin B12 Supplement
  - 8.1.1.3. Vitamin D & Calcium Supplement
8.2. Middle East & Africa Sarcopenia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Hospital Pharmacies
  - 8.2.1.2. Retail Pharmacies
  - 8.2.1.3. Online Pharmacies
  - 8.2.1.4. Hypermarket & Supermarket
8.3. Middle East & Africa Sarcopenia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Nigeria Sarcopenia Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Sarcopenia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.11. Rest of Middle East & Africa Sarcopenia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Treatment Type vs Distribution Channel Heatmap
9.2. Manufacturer vs Distribution Channel Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Abbott Laboratories
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Treatment Type Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Pfizer Inc.
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Treatment Type Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Novartis AG
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Treatment Type Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. GlaxoSmithKline Plc.
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Treatment Type Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Nestle S.A.
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Treatment Type Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Bayer AG
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Treatment Type Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. Sanofi S.A.
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Treatment Type Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Amway
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Treatment Type Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. Cadila Healthcare Ltd.
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Treatment Type Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. Eli Lilly and Company
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Treatment Type Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations